
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5209617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Impact of a Precision-Based Exercise Intervention in Childhood Hematological Malignancies Evaluated by an Adapted Yo-Yo Intermittent Recovery Test. Cancers, 2022, 14, 1187.	3.7	3
2	Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond. Frontiers in Pediatrics, 2022, 10, 807992.	1.9	5
3	Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a singleâ€centre cohort. British Journal of Haematology, 2022, , .	2.5	2
4	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2022, 36, 1508-1515.	7.2	21
5	ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	2.4	3
6	The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplantation, 2021, 56, 257-266.	2.4	11
7	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	1.6	163
8	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers, 2021, 13, 2075.	3.7	23
9	COVID-19 in Immunosuppressed Children. Frontiers in Pediatrics, 2021, 9, 629240.	1.9	30
10	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Pediatrics, 2021, 9, 705179.	1.9	22
11	Serum anti-Müllerian hormone as a marker of ovarian reserve after cancer treatment and/or hematopoietic stem cell transplantation in childhood: proposal for a systematic approach to gonadal assessment. European Journal of Endocrinology, 2021, 185, 717-728.	3.7	5
12	Immunological response after mild COVID-19: How long will it last?. EBioMedicine, 2021, 72, 103597.	6.1	1
13	Late Effects After Haematopoietic Stem Cell Transplantation in ALL, Long-Term Follow-Up and Transition: A Step Into Adult Life. Frontiers in Pediatrics, 2021, 9, 773895.	1.9	14
14	Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions. Frontiers in Pediatrics, 2021, 9, 774348.	1.9	15
15	Osteopathic Treatment and Evaluation in the Clinical Setting of Childhood Hematological Malignancies. Cancers, 2021, 13, 6321.	3.7	1
16	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. Lancet Haematology,the, 2020, 7, e902-e911.	4.6	18
17	High <i>EVI1</i> Expression due to <i>NRIP1/EVI1</i> Fusion in Therapyâ€related Acute Myeloid Leukemia: Description of the First Pediatric Case. HemaSphere, 2020, 4, e471.	2.7	3
18	COVIDâ€19 – Impact on Childhood Haematology Patients. HemaSphere, 2020, 4, e465.	2.7	9

#	Article	IF	CITATIONS
19	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	2.4	42
20	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1126-1136.	2.4	23
21	Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 2020, 132, 11-16.	2.8	155
22	Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplantation, 2020, 55, 1900-1905.	2.4	104
23	Children with cancer in the time of COVIDâ€19: An 8â€week report from the six pediatric oncoâ€hematology centers in Lombardia, Italy. Pediatric Blood and Cancer, 2020, 67, e28410.	1.5	82
24	Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transplantation, 2020, 55, 1918-1927.	2.4	28
25	Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	8.2	102
26	Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO) Journal of Clinical Oncology, 2020, 38, 10518-10518.	1.6	10
27	Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2197-2210.	2.0	30
28	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Advances, 2019, 3, 3393-3405.	5.2	81
29	Avascular necrosis of the talus in pediatric acute lymphoblastic leukemia: current concepts. Minerva Ortopedica E Traumatologica, 2019, 70, .	0.3	1
30	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	27.0	3,680
31	Outcome of relapse after allogeneic <scp>HSCT</scp> in children with <scp>ALL</scp> enrolled in the <scp>ALL</scp> â€ <scp>SCT</scp> 2003/2007 trial. British Journal of Haematology, 2018, 180, 82-89.	2.5	50
32	Unrelated donor vs HLA-haploidentical α/β T-cell– and B-cell–depleted HSCT in children with acute leukemia. Blood, 2018, 132, 2594-2607.	1.4	101
33	Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 1848-1855.	2.0	27
34	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 2018, 32, 1657-1669.	7.2	86
35	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2070-2078.	2.0	48
36	The Value of Minimal Residual Disease (and Diamonds). Biology of Blood and Marrow Transplantation, 2017, 23, 3-5.	2.0	3

#	Article	IF	CITATIONS
37	Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia. Pediatric Transplantation, 2016, 20, 158-161.	1.0	4
38	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Oncotarget, 2016, 7, 82123-82138.	1.8	6
39	Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. British Journal of Haematology, 2014, 164, 396-408.	2.5	76
40	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2014, 20, 375-381.	2.0	181
41	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica, 2013, 98, 1273-1281.	3.5	30
42	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases. 2013. 57, 794-802.	5.8	196
43	Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. Haematologica, 2013, 98, 1624-1632.	3.5	27
44	Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. Stem Cells International, 2012, 2012, 1-6.	2.5	28
45	Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood, 2012, 119, 2935-2942.	1.4	82
46	Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of Blood and Marrow Transplantation, 2012, 18, 852-860.	2.0	18
47	No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood, 2011, 118, 6683-6690.	1.4	45
48	Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after lowâ€risk relapse. Pediatric Blood and Cancer, 2011, 57, 654-659.	1.5	7
49	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. Biology of Blood and Marrow Transplantation, 2010, 16, 1293-1301.	2.0	165
50	Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood, 2010, 115, 3437-3446.	1.4	159
51	Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood, 2009, 114, 709-718.	1.4	210
52	Early (Day â^'7) versus Conventional (Day â^'1) Inception of Cyclosporine-A for Graft-versus-Host Disease Prophylaxis after Unrelated Donor Hematopoietic Stem Cell Transplantation in Children. Long-Term Results of an AIEOP Prospective, Randomized Study. Biology of Blood and Marrow Transplantation, 2009, 15, 741-748.	2.0	4
53	Regulatory T Cells and Extracorporeal Photochemotherapy: Correlation With Clinical Response and Decreased Frequency of Proinflammatory T Cells. Transplantation, 2009, 87, 1422-1425.	1.0	70
54	Interleukin-17–Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. Transplantation, 2009, 88, 1261-1272.	1.0	108

#	Article	IF	CITATIONS
55	Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica, 2008, 93, 925-929.	3.5	23
56	Transplantation in Childhood Very High Risk Acute Lymphoblastic Leukemia in First Complete Remission: Where Are We Now?. Journal of Clinical Oncology, 2007, 25, 2625-2626.	1.6	4
57	Extracorporeal Photochemotherapy Is Accompanied by Increasing Levels of Circulating CD4+CD25+GITR+Foxp3+CD62L+ Functional Regulatory T-Cells in Patients With Graft-Versus-Host Disease. Transplantation, 2007, 84, 31-39.	1.0	136
58	Extracorporeal Photochemotherapy for the Treatment of Chronic Graft-Versus-Host Disease: Trend for a Possible Cell Dose-Related Effect?. Therapeutic Apheresis and Dialysis, 2007, 11, 85-93.	0.9	61
59	Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation. British Journal of Haematology, 2005, 130, 249-255.	2.5	14
60	CD34+ Stem Cell Recovery After Positive Selection of "Overloaded" Immunomagnetic Columns. Stem Cells and Development, 2005, 14, 740-743.	2.1	12
61	Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet, The, 2005, 366, 635-642.	13.7	167
62	Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. British Journal of Haematology, 2003, 122, 118-127.	2.5	174
63	Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia, 2003, 17, 2247-2248.	7.2	20
64	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood, 2002, 100, 1192-1200.	1.4	201
65	Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vshost-disease (GvHD): Comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). Journal of Clinical Apheresis, 2002, 17, 65-71.	1.3	35
66	Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Gruppo Italiano Trapianto di Mid. British Journal of Haematology, 2001, 112, 796-805.	2.5	56
67	Febrile Complications in the First 100 Days After Bone Marrow Transplantation in Children: A Single Center's Experience. Pediatric Hematology and Oncology, 1997, 14, 335-347.	0.8	12
68	Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. British Journal of Haematology, 1997, 96, 387-394.	2.5	37
69	Nutritional Status in Untreated Children with Acute Leukemia as Compared with Children without Malignancy. Journal of Pediatric Gastroenterology and Nutrition, 1996, 23, 34-37.	1.8	44
70	Highâ€dose vincristine, fractionated totalâ€body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7â€year Italian multicentre study. British Journal of Haematology, 1995, 89, 790-797.	2.5	22